Kim, Hawk <br/><br/>
Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome.  [electronic resource] 

 -  British journal of haematology  09 2019 
 - e151-e155 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.15991  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--pharmacology<br/>Female<br/>Humans<br/>Lenalidomide--pharmacology<br/>Male<br/>Myelodysplastic Syndromes--drug therapy<br/>Prognosis<br/>Progression-Free Survival<br/>Survival Analysis